Ribocure Pharmaceuticals
Clinical-stage oligonucleotide therapeutics for rare diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $33.0m | Angel | |
| Total Funding | 000k | ||
| SEK | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 115 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| % profit margin | - | 1 % |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Ribocure Pharmaceuticals is a Swedish clinical-stage biotech company founded in 2022. It operates as the international R&D center for its parent company, Suzhou Ribo Life Science Co., Ltd. The company is led by CEO Dr. Li-ming Gan, a physician-scientist with two decades of experience at AstraZeneca, particularly in cardiovascular, renal, and metabolism drug development. Ribocure focuses on developing oligonucleotide therapeutics, such as siRNA (small interfering RNA) and ASO (antisense oligonucleotide), to address unmet medical needs in rare diseases, primarily within the cardiovascular, renal, and oncology sectors.
The company's business model is centered on a "bench-to-bedside" approach, integrating an R&D department, an in vitro human cell lab, and a specialized Phase 2 clinical trial unit called Ribocure Clinic, all housed within the GoCo Health Innovation City in Mölndal, Sweden. This integrated structure is designed to accelerate the drug development process, with a stated average time of 20-24 months from concept to clinical trials. Ribocure leverages its parent company's vertically integrated platform, including the RIBO-GalSTAR™ liver targeting technology, which is utilized in its drug candidates. In May 2024, the company received authorization from the Swedish Medicinal Product Agency to begin a Phase II trial for RBD4059, an anti-thrombotic siRNA drug targeting Factor XI for patients with stable coronary artery disease.
In July 2025, Ribocure secured a significant investment of USD 33 million from Swedish investors Erik Selin and Jacob Torell, which will be used to advance its multi-specific siRNA platform and proprietary CNS-delivery technology for cardiovascular and neurodegenerative disorders. This funding milestone supports the company's ambition to become a leading global company in RNA therapeutics.
Keywords: Oligonucleotide therapeutics, RNA therapeutics, siRNA, rare diseases, clinical-stage biotech, cardiovascular disease, oncology, renal disease, drug development, anti-thrombotic, Factor XI inhibitor, clinical trials, Suzhou Ribo Life Science, Li-ming Gan, GoCo Health Innovation City, biotechnology, life sciences, gene silencing, GalNAc